Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoxic cell specific chemotherapeutic agents.

A C Sartorelli

    Advances in Enzyme Regulation
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Targeting hypoxic tumor stem cells is crucial for cancer cure. Mitomycin C, a bioreductive alkylating agent, effectively eliminates these cells and should be considered in solid tumor treatment regimens.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges.

    Analytical biochemistry·2015
    Same author

    1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.

    Cancer chemotherapy and pharmacology·2004
    Same author

    1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.

    Cancer chemotherapy and pharmacology·2003
    Same author

    Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents.

    Nucleosides, nucleotides & nucleic acids·2002
    Same author

    Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells.

    Cancer research·2001
    Same author

    Inhibition of 20 S and 26 S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans retinoic acid.

    The Journal of biological chemistry·2001

    Area of Science:

    • Oncology
    • Cancer Biology
    • Pharmacology

    Background:

    • Solid tumors contain heterogeneous cell populations based on oxygenation and proliferation.
    • Eradicating tumor stem cells is essential for achieving a cure in solid neoplasms.
    • Hypoxic cells within tumors present a significant challenge to conventional therapies.

    Purpose of the Study:

    • To propose the inclusion of mitomycin C in therapeutic regimens for solid tumors.
    • To highlight the importance of targeting hypoxic stem cells for cancer treatment.
    • To discuss the differential mechanisms of mitomycin C's cytotoxicity in oxygenated versus hypoxic environments.

    Main Methods:

    • Review of the mechanisms of action of mitomycin C.
    • Analysis of the differential cytotoxicity of mitomycin C in oxygenated and hypoxic conditions.

    Related Experiment Videos

  • Consideration of drug delivery strategies to target hypoxic tumor cells.

    • Main Results:

    • Mitomycin C is a potent bioreductive alkylating agent effective against hypoxic stem cells.
    • The cytotoxicity of mitomycin C differs between oxygenated and hypoxic cells due to distinct reduction pathways.
    • Oxygenated cells generate toxic oxygen species from mitomycin C, contributing to its toxicity in normal tissues.

    Conclusions:

    • Mitomycin C is a promising agent for eliminating hypoxic stem cells in solid tumors.
    • Optimizing mitomycin C administration, potentially through low-dose continuous infusion, can maximize its efficacy against hypoxic cells while minimizing toxicity.
    • The differential mechanism of action supports the strategic use of mitomycin C in combination therapies for solid tumors.